aTYR PHARMA (ATYR) Free Cash Flow (2014 - 2026)

aTYR PHARMA (ATYR) has reported Free Cash Flow for 13 consecutive years, with -$9.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow rose 32.22% year-over-year to -$9.4 million; the trailing twelve-month figure through Jun 2026 stood at -$54.8 million (up 1.5% YoY), and the FY2025 full-year result was -$62.1 million, up 10.29% from the prior year.
• Free Cash Flow climbed to -$9.4 million in Q2 2026 per ATYR's latest filing, from -$12.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$1.8 million in Q1 2023 and bottomed at -$22.4 million in Q1 2024.
• Historically, Free Cash Flow has averaged -$13.0 million across 5 years, with a median of -$12.7 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 81.93% in 2023, then tumbled 1119.88% in 2024.
• Over 5 years, Free Cash Flow stood at -$11.5 million in 2022, then gained by 3.56% to -$11.1 million in 2023, then fell by 18.76% to -$13.2 million in 2024, then gained by 7.07% to -$12.2 million in 2025, then grew by 22.92% to -$9.4 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$9.4 million, -$12.7 million, and -$12.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.